A Ukrainian pharmaceutical technology company has been stranded and many early projects have been interrupted and delayed.


Release time:

2022-02-27

A pharmaceutical industry chain company trapped in the war in Ukraine is affecting the pace of global drug research and development, and many large pharmaceutical companies and biotechnology companies will be indirectly affected. In China, in this "black swan" incident on the global supply chain of medicine, the most affected may be scientific research institutions and some pharmaceutical companies that are at the forefront of innovation.

A pharmaceutical industry chain company trapped in the war in Ukraine is affecting the pace of global drug research and development, and many large pharmaceutical companies and biotechnology companies will be indirectly affected. In China, in this "black swan" incident on the global supply chain of medicine, the most affected may be scientific research institutions and some pharmaceutical companies that are at the forefront of innovation.

The Russo-Ukrainian war has already caused panic among biotech executives.

In the 30 years since the end of the Cold War, companies and laboratories developing new drugs have increasingly relied on a handful of Ukrainian companies to complete several key steps in the discovery of new drugs (new molecules), especially one company called Enamine.

Although Enamine does not disclose all of its customers, experts and industry insiders say the company's services are used throughout the pharmaceutical industry. It could also disrupt many early projects and cause months-long delays if its business is disrupted.

"Almost every company has ordered from Enamine to some extent." Derek Lowe, a senior pharmaceutical chemist in the industry, said, but he stressed that there are workarys. "Losing them will be painful, but there will be no serious consequences."

It is understood that the Enamine's products mainly cover synthetic blocks, screening libraries and fragment libraries. The total number of products in the library exceeds 100000, and the number of product types and varieties has absolute advantages in the same industry. Especially for some niche products, many Enamine are exclusive supply, the market is less alternative. It also has a large market share in the United States, Europe and Japan.

Enamine and its partners in Kiev, Ukraine, have been preparing contingency plans for months. But when the Russian shelling arrived in Kiev on Thursday, Enamine said shipments from Kiev had been suspended due to employee safety concerns and the headquarters was closed until Monday (February 28). But the company's U.S. branch is still operating.